

REGOLIX 120

(Relugolix 120 mg Tabs)

LAUNCHING

The superior oral
gonadotropin-releasing
hormone (GnRH)
antagonist¹



For the Treatment of Advanced Prostate Cancer in Men.

For the Treatment of Uterine Fibroids in Women.



In the trial involving men with advanced prostate cancer, relugolix (**REGOLIX**) achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a **54% lower risk of major adverse cardiovascular events.**

(NEGM June 2020)

Day 1 loading dose: 360 mg PO

Maintenance dose: 120 mg PO qDay



112,113,114 Crescent Business Park,
Sakinaka Telephone exchange Lane.
Andheri (East). Mumbai 400 072



www.mxmhealthcare.com
assist@mxmhealthcare.com
+91 22 4801 6166 / +91 22 4616 6610